The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice
Open accessAbstract
Protein tau filaments in brain of patients suffering from Alzheimer's disease, frontotemporal dementia, and other tauopathies consist of protein tau that is hyperphosphorylated. The responsible kinases operating in vivo in neurons still need to be identified. Here we demonstrate that glycogen synthase kinase-3beta (GSK-3beta) is an effective kinase for protein tau in cerebral neurons in vivo in adult GSK-3beta and GSK-3beta x human tau40 transgenic mice. Phosphorylated protein tau migrates slower during electrophoretic separation and is revealed by phosphorylation-dependent anti-tau antibodies in Western blot analysis. In addition, its capacity to bind to re-assembled paclitaxel (Taxol((R)))-stabilized microtubules is reduced, compared with protein tau isolated from mice not overexpressing GSK-3beta. Co-expression of GSK-3beta reduces the number of axonal dilations and alleviates the motoric impairment that was typical for single htau40 transgenic animals (Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R., and Van Leuven, F. (1999) Am. J. Pathol. 155, 2153-2165). Although more hyperphosphorylated protein tau is available, neither an increase in insoluble protein tau aggregates nor the presence of paired helical filaments or tangles was observed. These findings could have therapeutic implications in the field of neurodegeneration, as discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overexpression of GSK3 𝛃 in mice induces Tau hyperphosphorylation”
From Genetic modifiers of tauopathy in Drosophila (2003) · cites this paper as Spittaels et al. 2000
In the citing paper
“altered phosphorylation has been correlated with both increases ( Lucas et al. 2001) and decreases ( Spittaels et al. 2000) in neurodegeneration.”
From Genetic modifiers of tauopathy in Drosophila (2003) · cites this paper as Spittaels et al. 2000
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134
Mutation-Specific Functional Impairments in Distinct Tau Isoforms of Hereditary FTDP-17
Hong, M. (1998) · Science · doi:10.1126/science.282.5395.1914 · Cited by 1,003
Goedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929
Sutherland, C., Leighton, I. A., & Cohen, P. (1993) · Biochemical Journal · doi:10.1042/bj2960015 · Cited by 903
Cited by
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Role of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo
Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 509
Jackson, G. R., Wiedau-Pazos, M., Sang, T.-K., Wagle, N., Brown, C. A., Massachi, S., & Geschwind, D. H. (2002) · Neuron · doi:10.1016/s0896-6273(02)00706-7 · Cited by 488
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival
Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305838200 · Cited by 469
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
Glycogen synthase kinase 3: a drug target for CNS therapies
Bhat, R. V., Budd Haeberlein, S. L., & Avila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408
Glycogen synthase kinase 3: an emerging therapeutic target
Eldar-Finkelman, H. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02266-3 · Cited by 407
Leroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy
Kraemer, B. C., Zhang, B., Leverenz, J. B., Thomas, J. H., Trojanowski, J. Q., & Schellenberg, G. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533448100 · Cited by 379
Alquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367
Therapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
What Are the bona fide GSK3 Substrates?
Sutherland, C. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/505607 · Cited by 345
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
“The generation of these transgenic mice has been described in detail previously (Spittaels et al., 2000, 2002).”
MethodNishimura, I., Yang, Y., & Lu, B. (2004) · Cell · doi:10.1016/s0092-8674(04)00170-9 · Cited by 324
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Self-citationIs Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Cho, J., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02155.x · Cited by 282
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
Genetic modifiers of tauopathy in Drosophila
Shulman, J. M., & Feany, M. B. (2003) · Genetics · doi:10.1093/genetics/165.3.1233 · Cited by 275
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P., & Van Leuven, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409876200 · Cited by 272
Self-citationGlycogen Synthase Kinase 3β Phosphorylates Tau at Both Primed and Unprimed Sites
Cho, J.-H., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206236200 · Cited by 266
GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila
Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A. A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001483 · Cited by 265
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205
“Thus, our data suggest that the inheritance of the T allele of rs6438552 results in altered splicing in vivo to cause increased levels of GSK exon9 11, which, in turn, leads to increased phosphorylation of Tau.”
BackgroundInfluentialChatterjee, S., Sang, T.-K., Lawless, G. M., & Jackson, G. R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn326 · Cited by 178
GSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177
Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans
Kraemer, B. C., Burgess, J. K., Chen, J. H., Thomas, J. H., & Schellenberg, G. D. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl067 · Cited by 150
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease
Terwel, D., Dewachter, I., & Van Leuven, F. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:151 · Cited by 146
“Direct evidence for a role of GSK-3β in tau protein-related processes stems from our findings with single- and double-transgenic mice that overexpress htau-4R and/or GSK-3β (Spittaels et al., 1999, 2000).”
BackgroundInfluentialLi, T., & Paudel, H. K. (2006) · Biochemistry · doi:10.1021/bi051634r · Cited by 140
Fuchs, C., Trazzi, S., Torricella, R., Viggiano, R., De Franceschi, M., Amendola, E., Gross, C., Calzà, L., Bartesaghi, R., & Ciani, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.006 · Cited by 138
Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation
Wang, Y., Yang, R., Gu, J., Yin, X., Jin, N., Xie, S., Wang, Y., Chang, H., Qian, W., Shi, J., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.035 · Cited by 134
Tau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., MacDonald, C., Aboagye, A. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0889-12.2012 · Cited by 126
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
“Similarly, Tg mice expressing GSK-3b display increased tau phosphorylation, as well as learning and memory deficits (Spittaels et al. 2000; Lucas et al. 2001; Hernandez et al. 2002).”
BackgroundAmbegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113
Louis, J. V., Martens, E., Borghgraef, P., Lambrecht, C., Sents, W., Longin, S., Zwaenepoel, K., Pijnenborg, R., Landrieu, I., Lippens, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018777108 · Cited by 112
“As GSK3β is an established tau AT8/ AT180 kinase in vivo (8, 22, 41, 45, 46) this elevated GSK3β activity is the likely cause of tau hyperphosphorylation in the KO.”
BackgroundS/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila
Steinhilb, M. L., Dias‐Santagata, D., Mulkearns, E. E., Shulman, J. M., Biernat, J., Mandelkow, E., & Feany, M. B. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21232 · Cited by 107
Iijima, K., Gatt, A., & Iijima-Ando, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq200 · Cited by 96
Analysis of tauopathies with transgenic mice
Hutton, M., Lewis, J., Dickson, D., Yen, S.-H., & McGowan, E. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02123-2 · Cited by 91
Leroy, A., Landrieu, I., Huvent, I., Legrand, D., Codeville, B., Wieruszeski, J.-M., & Lippens, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149419 · Cited by 86
A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer’s Disease
Herrera-Espejo, S., Santos-Zorrozua, B., Álvarez-González, P., Lopez-Lopez, E., & Garcia-Orad, Á. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01676-9 · Cited by 81
Iijima-Ando, K., Zhao, L., Gatt, A., Shenton, C., & Iijima, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq068 · Cited by 72
Sen, T., Saha, P., Jiang, T., & Sen, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916895117 · Cited by 68
Johnson, G. V. W., & Bailey, C. D. C. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4505 · Cited by 61
Ferrer, I., Barrachina, M., Tolnay, M., Rey, M. J., Vidal, N., Carmona, M., Blanco, R., & Puig, B. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00007.x · Cited by 60
Ainani, H., Bouchmaa, N., Ben Mrid, R., & El Fatimy, R. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106011 · Cited by 54
“Alteration of tau phosphorylation has negative consequences on neurons’ functions and may lead to neurodegeneration (Spittaels et al., 2000; Tatebayashi et al., 2004; Jaworski et al., 2010).”
BackgroundBasurto-Islas, G., Gu, J.-H., Tung, Y. C., Liu, F., & Iqbal, K. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170715 · Cited by 39
Hoerndli, F. J., Pelech, S., Papassotiropoulos, A., & Götz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05618.x · Cited by 34
Metadata
- Authors
- Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., Van Lint, J., Vandenheede, J., Moechars, D., Loos, R., & Van Leuven, F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 275
- Issue
- 52
- Pages
- 41340-41349
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2139553041
- Cited by
- 316
- References
- 82
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.